	Somerset, N.J., – October 27, 2015 - Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health products and global clinical supply services, today announced that it is to quadruple cold chain capacity at its existing clinical supply storage and distribution facility in Shanghai, China. The expansion is in response to growing customer demand from both domestic and multinational pharmaceutical sponsors and contract research organizations (CROs).
	 
	Expansion work at the site is underway and is due to be fully validated and operational by the end of the year. Opened in 2013, the facility was the first in China to provide end-to-end clinical supply solutions from clinical supply management, comparator/reference product sourcing and primary packaging to clinical storage and distribution.
	 
	The cGMP site is also validated to support biologics requiring refrigerated and frozen supply chain management and currently offers 15º/25ºC controlled room temperature, 2º/8ºC refrigerated, -20ºC frozen and -80ºC ultra-low frozen storage environments. The new expansion includes the quadrupling of existing cold chain storage capacity, as well as new dedicated receiving, dispatch and packaging areas.
	 
	“In the two years since the facility opened, we have seen a sharp increase in the utilization of the site, with a shift towards more trials involving biologics and temperature sensitive drugs,” commented Wetteny Joseph, Catalent’s President of Clinical Supply Services.
	 
	Being located in the Shanghai Free Trade Zone, which is within close proximity of the Pudong and Hongqiao international airports, and other key transport links across China and the broader Asia Pacific region, Catalent’s Shanghai site benefits from expedited customs and clearance processes, as well as the potential elimination of duties, taxes and transportation delays.
	 
	Catalent also announced today that it had added further packaging and low temperature storage capacity to its Singapore facility, citing the need to support secondary packaging and innovative and flexible clinical supply services. “This expansion continues our strategic growth program within the Asia-Pacific region, and follows our announcement in June 2015, that we are increasing capacity at our Singapore clinical supply facility by 60%,” continued Joseph.
	 
	With facilities in the US, UK, Germany, Singapore and China, and an extended network of over 50 audited depots, Catalent’s clinical supply services team has the capability and expertise to handle a broad range of international compliance and distribution requirements, that can help to expedite clinical trials and ensure that customers are reliably supplied where and when needed around the globe.
	
	For more information on Catalent’s Clinical Supply services, please visit: 


	
	About Catalent
	
	Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and global clinical supply services. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit 